Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5

P. Riva, G. Paganelli, L. Callegaro, M. G. Bartoli, D. Turci, S. Benini, G. Deleide, G. A. Scassellati, G. Viale, A. G. Siccardi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

F(ab')2fragments of F023C5, an anti-CEA monoclonal antibody, were conjugated to diethylenet- riamine pentaacetic add (DTPA) and converted into a ready to use reagent for instant111In-labelling. The resulting nlIn radiopharmaceutical (2-3 mCi/0.5 mg of F(ab')2fragments) was administered intravenously and tested for its ability to image (at 48-72 h after administration) 31 primary and 85 metastatic carcinoma lesions in 70 adenocarcinoma patients (26 gastrointestinal, 18 breast and 26 lung tumour patients) whose serum CEA was elevated in 43 cases and normal in the other 27. The results were as follows: no adverse reactions or evidence of toxicity were observed in any of the patients. positive immunoscintigraphy results were obtained in 78% CEA-seropositive and in 64% seronegative patients. the fraction of documented lesions which was imaged was 69% in CEA-seropositive patients and 39% in seronegative patients. several 'unexpected' radiolocalizations were imaged; 30/34 were confirmed as (previously occult) tumour lesions in follow-up studies. In 6 patients, the immunoscintigraphic demonstration of previously occult lesions contributed to the early detection of tumour recurrences. the major limitation of the method is the non-specific radioactivity accumulation in the liver, which prevents the detection of liver metastases. in CEA-seropositive patients the fraction of imaged extra-hepatic tumour lesions is over 80%. the major cause of negative immunoscintigraphy results is lack of CEA in the tumour lesion, as demonstrated by immunohistochemistry of surgically removed tumours.

Original languageEnglish
Pages (from-to)577-589
Number of pages13
JournalNuclear Medicine Communications
Volume9
Issue number8
Publication statusPublished - 1988

Fingerprint

Adenocarcinoma
Monoclonal Antibodies
Neoplasms
Liver
Radiopharmaceuticals
Radioactivity
Breast
Immunohistochemistry
Neoplasm Metastasis
Carcinoma
Recurrence
Lung
Serum

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Riva, P., Paganelli, G., Callegaro, L., Bartoli, M. G., Turci, D., Benini, S., ... Siccardi, A. G. (1988). Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5. Nuclear Medicine Communications, 9(8), 577-589.

Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5. / Riva, P.; Paganelli, G.; Callegaro, L.; Bartoli, M. G.; Turci, D.; Benini, S.; Deleide, G.; Scassellati, G. A.; Viale, G.; Siccardi, A. G.

In: Nuclear Medicine Communications, Vol. 9, No. 8, 1988, p. 577-589.

Research output: Contribution to journalArticle

Riva, P, Paganelli, G, Callegaro, L, Bartoli, MG, Turci, D, Benini, S, Deleide, G, Scassellati, GA, Viale, G & Siccardi, AG 1988, 'Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5', Nuclear Medicine Communications, vol. 9, no. 8, pp. 577-589.
Riva, P. ; Paganelli, G. ; Callegaro, L. ; Bartoli, M. G. ; Turci, D. ; Benini, S. ; Deleide, G. ; Scassellati, G. A. ; Viale, G. ; Siccardi, A. G. / Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5. In: Nuclear Medicine Communications. 1988 ; Vol. 9, No. 8. pp. 577-589.
@article{fadfdb4c8eea47238ff179ca8af58159,
title = "Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5",
abstract = "F(ab')2fragments of F023C5, an anti-CEA monoclonal antibody, were conjugated to diethylenet- riamine pentaacetic add (DTPA) and converted into a ready to use reagent for instant111In-labelling. The resulting nlIn radiopharmaceutical (2-3 mCi/0.5 mg of F(ab')2fragments) was administered intravenously and tested for its ability to image (at 48-72 h after administration) 31 primary and 85 metastatic carcinoma lesions in 70 adenocarcinoma patients (26 gastrointestinal, 18 breast and 26 lung tumour patients) whose serum CEA was elevated in 43 cases and normal in the other 27. The results were as follows: no adverse reactions or evidence of toxicity were observed in any of the patients. positive immunoscintigraphy results were obtained in 78{\%} CEA-seropositive and in 64{\%} seronegative patients. the fraction of documented lesions which was imaged was 69{\%} in CEA-seropositive patients and 39{\%} in seronegative patients. several 'unexpected' radiolocalizations were imaged; 30/34 were confirmed as (previously occult) tumour lesions in follow-up studies. In 6 patients, the immunoscintigraphic demonstration of previously occult lesions contributed to the early detection of tumour recurrences. the major limitation of the method is the non-specific radioactivity accumulation in the liver, which prevents the detection of liver metastases. in CEA-seropositive patients the fraction of imaged extra-hepatic tumour lesions is over 80{\%}. the major cause of negative immunoscintigraphy results is lack of CEA in the tumour lesion, as demonstrated by immunohistochemistry of surgically removed tumours.",
author = "P. Riva and G. Paganelli and L. Callegaro and Bartoli, {M. G.} and D. Turci and S. Benini and G. Deleide and Scassellati, {G. A.} and G. Viale and Siccardi, {A. G.}",
year = "1988",
language = "English",
volume = "9",
pages = "577--589",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Immunoscintigraphy of adenocarcinomas by means of111In-labelled F(Ab')2fragments of anti-CEA monoclonal antibody F023C5

AU - Riva, P.

AU - Paganelli, G.

AU - Callegaro, L.

AU - Bartoli, M. G.

AU - Turci, D.

AU - Benini, S.

AU - Deleide, G.

AU - Scassellati, G. A.

AU - Viale, G.

AU - Siccardi, A. G.

PY - 1988

Y1 - 1988

N2 - F(ab')2fragments of F023C5, an anti-CEA monoclonal antibody, were conjugated to diethylenet- riamine pentaacetic add (DTPA) and converted into a ready to use reagent for instant111In-labelling. The resulting nlIn radiopharmaceutical (2-3 mCi/0.5 mg of F(ab')2fragments) was administered intravenously and tested for its ability to image (at 48-72 h after administration) 31 primary and 85 metastatic carcinoma lesions in 70 adenocarcinoma patients (26 gastrointestinal, 18 breast and 26 lung tumour patients) whose serum CEA was elevated in 43 cases and normal in the other 27. The results were as follows: no adverse reactions or evidence of toxicity were observed in any of the patients. positive immunoscintigraphy results were obtained in 78% CEA-seropositive and in 64% seronegative patients. the fraction of documented lesions which was imaged was 69% in CEA-seropositive patients and 39% in seronegative patients. several 'unexpected' radiolocalizations were imaged; 30/34 were confirmed as (previously occult) tumour lesions in follow-up studies. In 6 patients, the immunoscintigraphic demonstration of previously occult lesions contributed to the early detection of tumour recurrences. the major limitation of the method is the non-specific radioactivity accumulation in the liver, which prevents the detection of liver metastases. in CEA-seropositive patients the fraction of imaged extra-hepatic tumour lesions is over 80%. the major cause of negative immunoscintigraphy results is lack of CEA in the tumour lesion, as demonstrated by immunohistochemistry of surgically removed tumours.

AB - F(ab')2fragments of F023C5, an anti-CEA monoclonal antibody, were conjugated to diethylenet- riamine pentaacetic add (DTPA) and converted into a ready to use reagent for instant111In-labelling. The resulting nlIn radiopharmaceutical (2-3 mCi/0.5 mg of F(ab')2fragments) was administered intravenously and tested for its ability to image (at 48-72 h after administration) 31 primary and 85 metastatic carcinoma lesions in 70 adenocarcinoma patients (26 gastrointestinal, 18 breast and 26 lung tumour patients) whose serum CEA was elevated in 43 cases and normal in the other 27. The results were as follows: no adverse reactions or evidence of toxicity were observed in any of the patients. positive immunoscintigraphy results were obtained in 78% CEA-seropositive and in 64% seronegative patients. the fraction of documented lesions which was imaged was 69% in CEA-seropositive patients and 39% in seronegative patients. several 'unexpected' radiolocalizations were imaged; 30/34 were confirmed as (previously occult) tumour lesions in follow-up studies. In 6 patients, the immunoscintigraphic demonstration of previously occult lesions contributed to the early detection of tumour recurrences. the major limitation of the method is the non-specific radioactivity accumulation in the liver, which prevents the detection of liver metastases. in CEA-seropositive patients the fraction of imaged extra-hepatic tumour lesions is over 80%. the major cause of negative immunoscintigraphy results is lack of CEA in the tumour lesion, as demonstrated by immunohistochemistry of surgically removed tumours.

UR - http://www.scopus.com/inward/record.url?scp=0023706136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023706136&partnerID=8YFLogxK

M3 - Article

C2 - 3173916

AN - SCOPUS:0023706136

VL - 9

SP - 577

EP - 589

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 8

ER -